The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1525
Telotristat Ethyl (Xermelo) for Carcinoid Syndrome Diarrhea
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved telotristat ethyl (Xermelo – Lexicon), a tryptophan hydroxylase inhibitor, for use in combination with a somatostatin analog (SSA) for treatment of carcinoid syndrome diarrhea inadequately controlled with SSA therapy alone. Telotristat ethyl is the first oral drug to be approved in the US for this indication.

THE DISORDER — Carcinoid syndrome occurs in about 20% of patients with neuroendocrine tumors.1 It is characterized by diarrhea, flushing, bronchoconstriction, and cardiac valvular fibrosis. These symptoms occur as a result of tumor production of biogenic amines such as serotonin and other peptide hormones. Serotonin plays a major role in the regulation of intestinal motility, secretion, and visceral sensitivity, and its overproduction is thought to be the main cause of carcinoid syndrome diarrhea.

STANDARD TREATMENT — ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Telotristat Ethyl (Xermelo) for Carcinoid Syndrome Diarrhea
Article code: 1525c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian